Mosaic Therapeutics has announced the appointment of Dr Stephen Shuttleworth as Chief Scientific Officer. 

Shuttleworth has been a Venture Partner at Samsara BioCapital, Palo Alto, US since 2019, where his responsibilities included R&D due diligence, new company creation and C-suite level company leadership. He previously served as CSO, COO and Executive Director for over 10 years at Karus Therapeutics and, prior to that, held scientific leadership positions in the UK, US and Canadian biotech industries.  

 Shuttleworth brings scientific expertise in small molecule cancer therapeutics R&D and medicinal chemistry. He has directed multiple small molecule therapeutics research programmes, primarily in cancer, and also in immunology and inflammation, metabolic disorders and infectious diseases.  

His work includes the design, research and preclinical development of three small molecule cancer therapeutics that completed Phase I clinical studies: Pictilisib (pan-class I PI3K), KA2237/CVL-237 (selective PI3K-b/d), and KA2507 (HDAC6).  

 “I am delighted to be joining Mosaic, and for the opportunity to work with this world-class team in its pursuit of cutting-edge, precision combination therapies for the treatment of patients with cancer,” Shuttleworth said. 

“Mosaic’s Synergistic Precision approach to the discovery of biomarker-defined, targeted therapies is truly innovative and I look forward to working alongside the team to realise the full potential of the company’s discovery platform and capabilities.” 

Bruno Quinney, Content Team, DDW